Cancer News: Skin
Novartis’s oral pill, Odomzo, received approval by the U.S. FDA to treat patients with basal cell carcinoma, the most common form of advanced skin cancer.
The European Commission has approved nivolumab for the treatment of advanced melanoma patients. The approval is based on positive data from two phase 3 studies.
Combining the immunotherapies nivolumab and ipilimumab or using nivolumab alone resulted in better survival outcomes in advanced melanoma patients.
Advanced-stage melanoma patients treated with a genetically-modified form of a herpes virus had an especially prominent improvement in response and overall survival.
Melanoma patients rendered surgically free of disease but still at high risk survived longer without melanoma recurrence with the drug ipilimumab, a new study reports.
Pembrolizumab (label name: Keytruda), an immunotherapy agent, has received positive opinion from the European regulators for the treatment of advanced melanoma.
Amgen's skin cancer immunotherapy was recommended for approval by the FDA regardless of the uncertainties around the design and the results of the key study.
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
The immunotherapy drug nivolumab (trade name: Opdivo) received positive recommendation for treating advanced melanoma in Europe, after FDA approval in USA.
Melanoma patients who received a combination of two immunotherapies lived longer without disease progression with drugs combined than with one of those drugs alone.
Combining immunotherapy and cancer-targeted treatment shows more promising signs of more effectively controlling of advanced melanoma than previous treatments.
Cancer drug pembrolizumab was accepted under UK’s early access scheme to treat patients with advanced melanoma. The drug is not yet available in Europe.
The US FDA has granted accelerated approval to nivolumab for the treatment of unresectable or metastatic melanoma.
Metastatic or unresectable melanoma is an aggressive disease. Patients whose tumor is not responding to current drug therapies have another treatment option.
A monoclonal antibody called nivolumab shows response signs with superior rate and longer duration compared to standard chemotherapy in advanced melanoma.
A world-first study shows that a targeted combination drug treatment can reduce the risk of disease progression and death in patients with advanced melanoma.
The US FDA has approved Pembrolizumab (trade name: Keytruda) for treating advanced or unresectable melanoma in patients not responding to other therapies.
New research shows that the risk of squamous cell carcinoma (the second most common type of skin cancer) increases by as much as 90% by sunbeds.
Patients with advanced melanoma, who have been treated with the monoclonal antibody, ipilimumab, can survive for up to ten years, according to the largest analysis of overall survival for these patients, presented at the 2013 European Cancer Congress (ECC2013).
People with the most dangerous type of skin cancer tend to stay out of the sun and wear extra sunscreen the year after being diagnosed. But a new small study suggests those precautions don't last.
Although most of the melanomas that harbor BRAF mutations respond dramatically to treatment with BRAF inhibitors, nearly all develop resistance to the drugs in less than a year, and previous studies showed that melanomas alter a cell signaling pathway called the MAPK pathway to become resistant.
Two newly identified molecular targets in some forms of skin cancer could lead to new treatment options for the disease.
Skin cancer (melanoma) progression within 5 years has been found more likely if neighboring (sentinel) lymph nodes had a specific marker.
Melanoma metastases can be diagnosed, staged and treated more effectively through a new radiopharmaceutical technique.
A skin cancer (melanoma) treatment combination from GlaxoSmithKline has won accelerated approval from US regulators.
A genetic mutation present in 10-20% of people in countries like Spain, Portugal, Italy and Israel may translate to higher skin cancer risk.
Higher levels of the protein vascular endothelial growth factor (VEGF) in blood was linked to poor response to ipilimumab immunotherapy skin cancer treatment.
Between 1970-2009, skin cancer in adults 40-60 years old has become 8 times more common. Women between 40-50 showed the highest increase among any demographic.
Intermediate & thick melanomas staged by biopsy were associated with better 10-year disease and metastasis-free survival, compared to wide excision and nodal observation. This was shown in the final results of a randomized trial.
Researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate.